S&P moves MedRisk view to stable

S&P said it revised the outlook for CP VI Bella Midco LLC (MedRisk) to stable from negative.

“The stable outlook reflects our view that MedRisk’s financial performance and credit metrics will improve modestly in 2021 as PT visits gradually increase during the year. We expect revenue growth of 5%-10% in 2021 and similar adjusted EBITDA growth, supported by a stable EBITDA margin. We expect leverage of 4.75x-5.25x and adjusted EBITDA interest coverage of 2.75x-3.25x by year-end 2021,” S&P said in a press release.

The agency also affirmed the B ratings on MedRisk and its first-lien debt as well as the second-lien term loan’s CCC+ rating.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.